As a therapeutic agent, most people are familiar with the palliative effects of the primary
psychoactive constituent of Cannabis sativa (CS), Δ 9-tetrahydrocannabinol (THC), a …

Objectives: The aim of this review is to discuss cannabinoids from a preclinical and clinical
oncological perspective and provide the audience with a concise, retrospective overview of …

Drugs that target the endocannabinoid system are of interest as pharmacological options to
combat cancer and to improve the life quality of cancer patients. From this perspective …

Cannabinoids are a class of pharmacologic compounds that offer potential applications as
antitumor drugs, based on the ability of some members of this class to limit inflammation, cell …

Cannabinoids, the active components of Cannabis sativa (marijuana), and their derivatives
produce a wide spectrum of central and peripheral effects, some of which may have clinical …

According to the World Health Organization, the cases of death caused by cancer will have
been doubled until the year 2030. By 2010, cancer is expected to be the number one cause …

In addition to the well-known palliative effects of cannabinoids on some cancer-associated
symptoms, a large body of evidence shows that these molecules can decrease tumour …

Cannabinoids have been attracting a great deal of interest as potential anticancer agents.
Originally derived from the plant Cannabis sativa, there are now a number of endo-, phyto …

To date, cannabinoids have been allowed in the palliative medicine due to their analgesic
and antiemetic effects, but increasing number of preclinical studies indicates their anticancer …

The pharmacological importance of cannabinoids has been in study for several years.
Cannabinoids comprise of (a) the active compounds of the Cannabis sativa plant,(b) …